

Rallis/PR/03/2526/Corp

Rallis India Limited Q2 & H1 PAT grew by 4% & 35% YoY, respectively

Mumbai, 16 Oct 2025: Rallis India Limited (A TATA Enterprise) is a leading player in the Indian agri inputs industry announced its financial results for the quarter and half year ended September 30, 2025

Key Highlights: Q2 & H1 FY26

Announcing the results, Dr Gyanendra Shukla, Managing Director & CEO, Rallis India Limited, said,

Despite challenging weather conditions, the company delivered **steady profitability and strong cash generation**, supported by cost optimization, disciplined operations and robust export growth.

During the quarter, the company recorded **revenue of ₹861 crore**, compared to ₹928 crore in Q2 FY25, reflecting a **7% decline** mainly due to erratic and prolonged rains in several parts of the country that impacted field activities and spray applications. **PAT grew by 4% to ₹102 crore**, compared to ₹98 crore in the corresponding quarter last year. The company's **PAT margin improved by 120 basis points to 11.8%**. **EBITDA for the quarter stood at ₹154 crore** as against ₹166 crore in Q2 FY25. Strong cash management continued with **Free Cash Flow of ₹52 crore**, **zero external debt**, and a **healthy closing cash and liquid balance of ₹454 crore**.

For the half year ended September 2025, Rallis reported revenue of ₹1,818 crore, a 6% increase over ₹1,711 crore in H1 FY25. EBITDA grew by 16% to ₹303 crore compared to ₹261 crore last year, while PAT grew 35% to ₹197 crore against ₹146 crore in H1 FY25. The company achieved a PAT margin of 10.8%, up from 8.5% in the previous year, reflecting improved operational efficiency and a richer product mix.

Business Performance: Q2 FY26

In Q2, the **Crop Care B2B business grew by 14% YoY** on the back of volume revival in key molecules and better capacity utilization, while **Crop Protection B2C** business performance declined 10% YoY due to weather disruptions and erratic rainfall across major markets. **Soil & Plant Health (SPH)** business declined by 20%, due to regulatory challenges in the Biostimulants category.

However, **exports registered a growth of 33%** driven by higher volume in key molecules.

The **Seeds business** recorded revenue of ₹101 crore compared to ₹141 crore in Q2 FY25, primarily due to supply chain constraints, though higher gross margins and effective pricing helped mitigate the impact.

Rallis continued to expand its portfolio with **eight new product launches during H1 FY26**, including Penflor, Allato, Deeweed, Dodrio, Master Gold, Torris, Vaar and Teer, strengthening its position across herbicides and fungicides. The company also resumed biostimulant sales through in-house production, enhancing its footprint in sustainable crop solutions.

Management Comment

Commenting on the results, Dr. Gyanendra Shukla, Managing Director & CEO, Rallis India Limited, said:

Q2 was challenging due to prolonged rains which impacted field activities and product placement. Despite these headwinds, our profitability remained stable, supported by export momentum, prudent cost management, and improved margins in the Seeds business.

Our strong balance sheet, zero external debt and healthy cash position underscore our financial discipline and operational resilience.



About Rallis India:

Rallis India Limited is a subsidiary of Tata Chemicals Limited and a part of over US\$ 165 billion Tata Group. It is one of India's leading agri science companies, with more than 77 years of experience in serving rural markets with the most comprehensive portfolio of products/solutions for Indian farmers. Rallis is known for its deep understanding of Indian agriculture, sustained contact with farmers, quality agrochemicals, branding and marketing expertise along with its strong product portfolio in seeds and crop care which is available through a vast distribution network of 7,000 dealers and over 1,00,000 retailers across India. Rallis has marketing alliances with several multinational agrochemical companies. Rallis is also known for its manufacturing capabilities and ability to develop new processes and formulations; hence it is considered a preferred partner for contract manufacturing by leading global corporations.

For more information about other products in Rallis India's portfolio, please visit www.rallis.com

Follow us on:









For more information please contact:

Dr. Arpita Pattanaik **Corporate Communications** Rallis India Limited Mobile: 7008488328 arpita.pattanaik@rallis.com Karishma Changlani | Debipriya Bhattacharjee Adfactors PR Mobile -+91 7045483380 | 7044297304 karishma.changlani@adfactorspr.com debipriya.bhattacharjee@adfactorspr.com